Introduction
Bosentan Monohydrate is an oral medication classified as an endothelin receptor antagonist. It is primarily used to manage pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. Bosentan helps to improve exercise capacity and reduce symptoms associated with PAH.
Uses
Bosentan Monohydrate is used for:
- Treating pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms.
- Managing PAH in patients with both idiopathic and hereditary forms of the disease.
- Improving overall quality of life in patients with PAH.
| Brand Name | Bosentan Monohydrate |
|---|---|
| Type | |
| Weight | |
| Generic | Bosentan Monohydrate |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Bosentan works by blocking endothelin-1 (ET-1) receptors, which are involved in vasoconstriction and increased blood pressure. By antagonizing these receptors, bosentan leads to vasodilation (widening of blood vessels), thereby reducing blood pressure in the pulmonary arteries and improving blood flow.
How Long Does It Take to Work?
The effects of bosentan can usually be observed within 4 to 12 weeks of starting treatment. The medication may take some time to show significant improvements in exercise capacity and PAH symptoms, as it works gradually to reduce pulmonary arterial pressure.
Absorption
Bosentan is absorbed well from the gastrointestinal tract following oral administration. Its peak plasma concentration is typically reached within 3 to 5 hours. The presence of food does not significantly affect its absorption.
Route of Elimination
Bosentan is primarily metabolized in the liver through cytochrome P450 enzymes, particularly CYP2C9 and CYP3A4. The metabolites are then excreted in the bile and urine. Bosentan has minimal renal clearance.
Dosage
Tablets are to be taken orally morning and evening, with or without food.Pulmonary arterial hypertension: ln adult patients, Bosentan treatment should be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily.
For paediatric patients aged 2 years or older, the optimal maintenance dose has not been defined in well-controlled studies. However, paediatric pharmacokinetic data have shown that Bosentan plasma concentrations in children were on average lower than in adult patients and were not increased by increasing the dose of Bosentan above 2 mg/kg body weight twice daily.
Discontinuation of treatment: lf the decision to withdraw Bosentan is taken, it should be done gradually while an alternative therapy is introduced.
The recommended dosage of bosentan for adults is typically 62.5 mg twice daily for the first 4 weeks, followed by an increase to 125 mg twice daily if tolerated. The dosage may be adjusted based on patient response and tolerance. Dosage adjustments may be necessary for patients with liver impairment.
Administration
Bosentan is administered orally in the form of tablets. It should be taken with or without food, according to the prescribed schedule. Patients should follow the dosing instructions provided by their healthcare provider and not alter the dosage without medical advice.
Side Effects
Common side effects of bosentan include:
- Headache
- Dizziness
- Fatigue
- Swelling (edema)
- Nausea
- Rash
Toxicity
Toxicity from bosentan may manifest as liver dysfunction or elevated liver enzymes. Signs of liver toxicity include jaundice, dark urine, or persistent abdominal pain. Immediate medical attention is required if any symptoms of liver dysfunction occur.
Precautions
Precautions for bosentan include:
- Regular monitoring of liver function due to potential hepatotoxicity.
- Assessment of blood counts to detect anemia.
- Use with caution in patients with liver impairment or those receiving other medications that affect liver enzymes.
Interaction
Bosentan can interact with various medications, including:
- Other endothelin receptor antagonists or similar drugs.
- Medications that affect liver enzyme activity (e.g., CYP2C9 and CYP3A4 inhibitors or inducers).
- Oral contraceptives, which may need dosage adjustments.
Disease Interaction
Patients with liver disease or elevated liver enzymes should use bosentan with caution, as the drug can exacerbate liver dysfunction. Close monitoring and dose adjustments may be necessary for these patients.
Drug Interaction
Drug interactions with bosentan include:
- Increased risk of hepatotoxicity when used with other hepatotoxic drugs.
- Altered efficacy when used with CYP2C9 or CYP3A4 inducers/inhibitors.
Food Interactions
Food does not significantly affect the absorption of bosentan. The medication can be taken with or without food according to patient preference and convenience.
Pregnancy Use
Bosentan is classified as Category X for pregnancy, indicating that it is contraindicated during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception during treatment.
Lactation Use
The safety of bosentan during lactation is not well-established. It is recommended that breastfeeding be discontinued or bosentan be avoided during lactation due to potential risks to the infant.
Acute Overdose
In case of acute overdose, symptoms may include severe hypotension, dizziness, or liver dysfunction. Immediate medical attention is required to manage and treat the effects of overdose.
Contraindication
Bosentan is contraindicated in:
- Pregnant women (due to risk of fetal harm).
- Patients with severe liver impairment.
Use Direction
Follow the prescribed dosing regimen exactly as directed by a healthcare provider. Do not alter the dose or frequency without medical advice. Regular monitoring of liver function and blood counts is essential during treatment.
Storage Conditions
Store bosentan tablets at room temperature, away from moisture and light. Keep out of reach of children and dispose of any unused medication according to pharmacy guidelines.
Volume of Distribution
The volume of distribution for bosentan is approximately 16 liters. This indicates its distribution throughout the body’s tissues and fluids.
Half Life
The terminal half-life of bosentan is approximately 5 to 9 hours. The half-life can vary depending on individual patient factors and concurrent medications.
Clearance
Bosentan is primarily cleared by the liver. Its clearance rate may be affected by liver function and interactions with other medications that impact liver enzyme activity.
See in details version Bosentan Monohydrate also Bosentan Monohydrate in bangla
